LS Investment Advisors LLC Has $2.04 Million Stock Position in Pfizer Inc. (NYSE:PFE)

LS Investment Advisors LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 15.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 80,452 shares of the biopharmaceutical company’s stock after selling 14,560 shares during the quarter. LS Investment Advisors LLC’s holdings in Pfizer were worth $2,039,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the fourth quarter worth $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the fourth quarter worth $30,000. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Trading Up 0.3%

Shares of PFE stock opened at $23.42 on Thursday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a 50 day moving average price of $23.02 and a two-hundred day moving average price of $25.02. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $133.15 billion, a PE ratio of 16.61, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period last year, the firm posted $0.82 EPS. The firm’s revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.34%. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.